Trial Profile
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Dubermatinib (Primary)
- Indications Carcinoma; Cholangiocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Sumitomo Pharma; Sumitomo Pharma Oncology; Tolero Pharmaceuticals
- 31 Jan 2023 Status changed from active, no longer recruiting to completed.
- 23 Nov 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 23 Nov 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.